Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 2, 2015, Pages 115-128

  Devineni, Damayanthi ^a   Vaccaro, Nicole ^a   Murphy, Joe ^a   Curtin, Christopher ^a   Mamidi, Rao N V S ^a   Weiner, Sveta ^a   Wang, Shean Sheng ^a   Ariyawansa, Jay ^a   Stieltjes, Hans ^b   Wajs, Ewa ^b   Di Prospero, Nicholas A ^a   Rothenberg, Paul ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Drug drug interactions; P glyco protein; Pharmacokinetics UGT Mrp

Indexed keywords

CANAGLIFLOZIN; CYCLOSPORIN A; PROBENECID; RIFAMPICIN; CYCLOSPORIN; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; GLYCEMIC CONTROL; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; OPEN STUDY; SINGLE DRUG DOSE; STEADY STATE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG INTERACTION;

ADULT; CANAGLIFLOZIN; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; GLUCOSIDES; HUMANS; MALE; PROBENECID; RIFAMPIN; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84961290698     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202158     Document Type: Article

References (47)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyper-glycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35: 1364-1379. CrossRef PubMed
2. Lamos EM, Younk LM, Davis SN. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013; 9: 763-775. CrossRef PubMed
3. Molitch ME. Current state of type 2 diabetes management. Am J Manag Care. 2013; 19 (Suppl): S136-S142. PubMed
4. Gross JL, Kramer CK, Leitão CB, Hawkins N, Viana LV, Schaan BD, Pinto LC, Rodrigues TC, Azevedo MJ; Diabetes and Endocrinology Meta-analysis Group (DEMA). Effect of antihypergly-cemic agents added to metformin and a sulfonyl-urea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med. 2011; 154: 672-679. PubMed
5. Chao EC, Henry RR. SGLT2 inhibition - a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010; 9: 551-559. CrossRef PubMed
6. Canagliflozin (Invokana") Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2013. Accessed on May 20, 2014; Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/204042s000lbl.pdf.
7. Canagliflozin (Invokana") Summary of Product Characteristics. Beerse, Belgium: Janssen-Cilag International N V. 2013. Accessed on May 20, 2014; Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002649/WC500156456.pdf.
8. Elkinson S, Scott LJ. Canagliflozin: first global approval. Drugs. 2013; 73: 979-988. CrossRef PubMed
9. Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, Farrell K, Rothenberg P, Henry RR. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013; 36: 2154-2161. CrossRef PubMed
10. Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995). 2013; 41: 72-84. CrossRef PubMed
11. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg P. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011; 13: 669-672. CrossRef PubMed
12. Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, Rusch S, Rothenberg PL. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2013; 53: 601-610. CrossRef PubMed
13. Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J, Ways K, Schwartz S. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012; 14: 539-545. CrossRef PubMed
14. Mamidi RN, Cuyckens F, Chen J, Scheers E, Kalamaridis D, Lin R, Silva J, Sha S, Evans DC, Kelley MF, Devineni D, Johnson MD, Lim HK. Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans. Drug Metab Dispos. 2014; 42: 903-916. CrossRef. PubMed
15. Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchart JC, Staels B. Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuroni-dating UDP-glucuronosyltransferase 2B4 enzyme. J Biol Chem. 2003; 278: 32852-32860. CrossRef PubMed
16. Münzel PA, Schmohl S, Heel H, Kälberer K, Bock-Hennig BS, Bock KW. Induction of human UDP glucuronosyltransferases (UGT1A6, UGT1A9, and UGT2B7) by t-butylhydroquinone and 2,3,7,8-tetrachlorodibenzo-p-dioxin in Caco-2 cells. Drug Metab Dispos. 1999; 27: 569-573. PubMed
17. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, Eichelbaum M, Siegmund W, Schrenk D. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol. 2000; 157: 1575-1580. CrossRef PubMed
18. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999; 104: 147-153. CrossRef PubMed
19. Magnarin M, Morelli M, Rosati A, Bartoli F, Candussio L, Giraldi T, Decorti G. Induction of proteins involved in multidrug resistance (P-gly-coprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK1 cells. Eur J Pharmacol. 2004; 483: 19-28. CrossRef PubMed
20. Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther. 2001; 299: 849-857. PubMed
21. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. P-glycoprotein: a major determinant of rifam-picin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA. 1996; 93: 4001-4005. CrossRef PubMed
22. Pui K, Gow PJ, Dalbeth N. Efficacy and tolerabil-ity of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol. 2013; 40: 872-876. Cross-Ref PubMed
23. Uchaipichat V, Mackenzie PI, Guo XH, GardnerStephen D, Galetin A, Houston JB, Miners JO. Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and proben-ecid. Drug Metab Dispos. 2004; 32: 413-423. CrossRef PubMed
24. Chu X Y, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun M P, Dean DC, Evers R. Transport of the dipeptidyl pepti-dase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypep-tide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007; 321: 673-683. Cross-Ref PubMed
25. Smeets PH, van Aubel RA, Wouterse AC, van den Heuvel JJ, Russel FG. Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identi-fication of MRP4 (ABCC4) as a novel PAH transporter. J Am Soc Nephrol. 2004; 15: 2828-2835. CrossRef PubMed
26. Tahara H, Kusuhara H, Maeda K, Koepsell H, Fuse E, Sugiyama Y. Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab Dispos. 2006; 34: 743-747. CrossRef PubMed
27. Food and Drug Administration (FDA). Guidance for Industry. Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations (2012). Accessed on May 20, 2014; Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf.
28. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev. 2003; 55: 425-461. CrossRef PubMed
29. Food and Drug Administration (FDA). Guidance for Industry, Bioanalytical Methods Validation (2001). Accessed on May 20, 2014; Available at: http://www.fda.gov/cder/guidance/4252fnl.htm.
30. Viswanathan C, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, Shah V P, Skelly JP, Swann PG, Weiner R. Workshop/conference report-quantitative bioanalytical methods validation and implementation: best practices for chromato-graphic and ligand binding assays. AAPS J. 2007; 9: E30-E42. CrossRef
31. Acocella G. Clinical pharmacokinetics of rifampi-cin. Clin Pharmacokinet. 1978; 3: 108-127. CrossRef PubMed
32. Bonakdaran S, Hami M, Shakeri MT. Hyperuricemia and albuminuria in patients with type 2 diabetes mellitus. Iran J Kidney Dis. 2011; 5: 21-24. PubMed
33. Polasa K, Krishnaswamy K. Effect of food on bioavailability of rifampicin. J Clin Pharmacol. 1983; 23: 433-437. CrossRef PubMed
34. Selen A, Amidon GL, Welling PG. Pharmacokinetics of probenecid following oral doses to human volunteers. J Pharm Sci. 1982; 71: 1238-1242. CrossRef PubMed
35. Rebello S, Compain S, Feng A, Hariry S, Dieterich HA, Jarugula V. Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects. J Clin Pharmacol. 2011; 51: 1549-1560. CrossRef PubMed
36. Sen S, Sinha S. Canagliflozin (Invokana®): A First-in-class anti-diabetic drug. Journal of Drug Delivery and Therapeutics. 2013; 3: 145-146
37. Dahlin MG, Wide K, Ohman I. Age and comedi-cations influence levetiracetam pharmacokinetics in children. Pediatr Neurol. 2010; 43: 231-235. CrossRef PubMed
38. Rifampin (Rifadin®) Prescribing Information. 2013. Bridgewater, NJ: sanofi-aventis, LLC. 2013. Accessed on May 20, 2014; Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/050420s075,050627s014lbl.pdf.
39. Harrison B, Magee MH, Mandagere A, Walker G, Dufton C, Henderson LS, Boinpally R. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study. Clin Drug Investig. 2010; 30: 875-885. CrossRef PubMed
40. Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013; 56: 2582-2592. CrossRef PubMed
41. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W; Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodium-glucose co-transporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012; 35: 1232-1238. CrossRef PubMed
42. Wilding J P, Charpentier G, Hollander P, González-Gálvez G, Mathieu C, Vercruysse F, Usiskin K, Law G, Black S, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonyl-urea: a randomised trial. Int J Clin Pract. 2013; 67: 1267-1282. CrossRef PubMed
43. Arif H, Svoronos A, Resor SR Jr, Buchsbaum R, Hirsch LJ. The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy. Epilepsia. 2011; 52: 1905-1913. CrossRef PubMed
44. Abernethy DR, Greenblatt DJ, Ameer B, Shader RI. Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. J Pharmacol Exp Ther. 1985; 234: 345-349. PubMed
45. Brockmeyer NH, Mertins L, Klimek K, Goos M, Ohnhaus EE. Comparative effects of rifampin and/or probenecid on the pharmacokinetics of temazepam and nitrazepam. Int J Clin Pharmacol Ther Toxicol. 1990; 28: 387-393. PubMed
46. Sarich T, Devineni D, Ghosh A. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, increases 24-hour urinary glucose excretion and reduces body weight in obese subjects over 2 weeks of treatment. Poster presented at: The 46th European Association for the Study of Diabetes (EASD) Annual Meeting, September 20-24, 2010, Stockholm, Sweden. Abstract #874. [NAP1008 and OBE 2001].
47. Sha S, Polidori D, Heise T, Natarajan J, Farrell K, Wang SS, Sica D, Rothenberg P, Plum-Mörschel L. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014; 16: 1087-1095. CrossRef PubMed